A randomized controlled trial of intranasal ketamine in migraine with prolonged aura

Neurology

Volumn 80, Issue 7, 2013, Pages 642-647

  Afridi, Shazia K ^a,b   Giffin, Nicola J ^a,c   Kaube, Holger ^a,d   Goadsby, Peter J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b GUY S HOSPITAL   (United Kingdom)

^c ROYAL UNITED HOSPITAL   (United Kingdom)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

FLUNARIZINE; KETAMINE; MIDAZOLAM; PIZOTIFEN; PROPRANOLOL; VALPROIC ACID; ANALGESIC AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEPERSONALIZATION; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EUPHORIA; FEMALE; HUMAN; MALE; MIGRAINE WITH AURA; NEUROTRANSMISSION; PARALLEL DESIGN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEDATION; SIDE EFFECT; TREATMENT OUTCOME; CONTROLLED CLINICAL TRIAL; HOSPITAL PATIENT; INTRANASAL DRUG ADMINISTRATION; LONGITUDINAL STUDY; METHODOLOGY; MIDDLE AGED; OUTPATIENT; SEVERITY OF ILLNESS INDEX; STATISTICS;

ADMINISTRATION, INTRANASAL; ADULT; ANALGESICS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INPATIENTS; KETAMINE; LONGITUDINAL STUDIES; MALE; MIDAZOLAM; MIDDLE AGED; MIGRAINE WITH AURA; OUTPATIENTS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

MLCS; MLOWN;

EID: 84875837888     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3182824e66     Document Type: Article

References (38)

1. Launer LJ, Terwindt GM, Ferrari MD. The prevalence and characteristics of migraine in a population-based cohort: the GEM study. Neurology 1999;53:537-542.
2. Kelman L. The aura: a tertiary care study of 952 migraine patients. Cephalalgia 2004;24:728-934.
3. Rasmussen BK, Jensen R, Olesen J. A population-based analysis of the diagnostic criteria of the International Headache Society. Cephalalgia 1991;11:129-134.
4. Russell MB, Iversen HK, Olesen J. Improved description of the migraine aura by a diagnostic aura diary. Cephalalgia 1994;14:107-117.
5. Headache Classification Committee of The International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988;8:1-96.
6. Leao AAP. Spreading depression of activity in cerebral cortex. J Neurophysiol 1944;7:359-390.
7. Lauritzen M. Pathophysiology of the migraine aura: the spreading depression theory. Brain 1994;117:199-210.
8. Hadjikhani N, Sanchez del Rio M, Wu O, et al. Mechanisms of migraine aura revealed by functional MRI in human visual cortex. Proc Natl Acad Sci USA 2001;98:4687-4692.
9. Bowyer SM, Aurora KS, Moran JE, Tepley N, Welch KM. Magnetoencephalographic fields from patients with spontaneous and induced migraine aura. Ann Neurol 2001;50: 582-587.
10. van den Maagdenberg AMJM, Pietrobon D, Pizzorusso T, et al. A Cacna1a knock-in migraine mouse model with increased susceptibility to cortical spreading depression. Neuron 2004;41:701-710.
11. Rozen TD. Aborting a prolonged migrainous aura with intravenous prochlorperazine and magnesium sulfate. Headache 2003;43:901-903.
12. Kowacs PA, Piovesan EJ, Tatsui CE, et al. Prolonged migraine aura without headache arrested by sumatriptan: a case report with further considerations. Cephalalgia 1999;19:241-242.
13. Rozen TD. Treatment of a prolonged migrainous aura with intravenous furosemide. Neurology 2000;55:732-733.
14. Rothrock JF. Successful treatment of persistent migraine aura with divalproex sodium. Neurology 1997;48:261-262.
15. Goldner JA, Levitt LP. Treatment of complicated migraine with sublingual nifedipine. Headache 1987;27:484-486.
16. Kaube H, Herzog J, Kaufer T, Dichgans M, Diener HC. Aura in some patients with familial hemiplegic migraine can be stopped by intranasal ketamine. Neurology 2000; 55:139-141.
17. Rashidy-Pour A, Motaghed-Larijani Z, Bures J. Tolerance to ketamine-induced blockade of cortical spreading depression transfers to MK-801 but not to AP5 in rats. Brain Res 1995;693:64-69.
18. Russell MB, Olesen J. A nosographic analysis of the migraine aura in a general population. Brain 1996;119: 355-361.
19. Headache Classification Committee of The International Headache Society. The International Classification of Headache Disorders, 2nd ed. Cephalalgia 2004;24:1-160.
20. Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika 1986;73:13-22.
21. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986;42:121-130.
22. Chen X, Shu S, Bayliss DA. HCN1 channel subunits are a molecular substrate for hypnotic actions of ketamine. J Neurosci 2009;29:600-609.
23. Zarantonello P, Bettini E, Paio A, et al. Novel analogues of ketamine and phencyclidine as NMDA receptor antagonists. Bioorg Med Chem Lett 2011;21:2059-2063.
24. Kulbe J. The use of ketamine nasal spray for short-term analgesia. Home Health Nurse 1998;16:367-370.
25. Abrams R, Morrison JE, Villasenor A, et al. Safety and effectiveness of intranasal administration of sedative medications (ketamine, midazolam, or sufentanil) for urgent brief pediatric dental procedures. Anesth Prog 1993;40:63-66.
26. Carr DB, Goudas LC, Denman WT, et al. Safety and efficacy of intranasal ketamine for the treatment of breakthrough pain in patients with chronic pain: a randomized, double-blind, placebo-controlled, crossover study. Pain 2004;108:17-27.
27. Marin J, Stefanovic A, Ganrenbein AR, et al. Nociception-specific blink reflex: a double-blinded placebo-controlled pharmacological study in 21 healthy males. Cephalalgia 2007;27:737-738.
28. Lauritzen M, Hansen AJ. The effect of glutamate receptor blockade on anoxic depolarization and cortical spreading depression. J Cereb Blood Flow Metab 1992; 12:223-229.
29. Marrannes R, Willems R, De Prins E, Wauquier A. Evidence for a role of the N-methyl-D-aspartate (NMDA) receptor in cortical spreading depression in the rat. Brain Res 1988;457:226-240.
30. Kruger H, Heinemann U, Luhmann HJ. Effects of iono-tropic glutamate receptor blockade and 5-HT1A receptor activation on spreading depression in rat neocortical slices. Neuroreport 1999;10:2651-2656.
31. Kaube H, Goadsby PJ. Anti-migraine compounds fail to modulate the propagation of cortical spreading depression in the cat. Eur Neurol 1994;34:30-35.
32. Netsiri S, Bradley DP, Takeda T, et al. A delayed class of BOLD waveforms associated with spreading depression in feline cerebral cortex can be detected and characterised using independent component analysis (ICA). Magn Reson Imaging 2003;21:1097-1110.
33. Strebel S, Kaufmann M, Maitre L, Schaefer HG. Effects of ketamine on cerebral blood flow velocity in humans. Influence of pretreatment with midazolam or esmolol. Anaesthesia 1995;50:223-228.
34. Yassin M, Scholfield CN. NMDA antagonists increase recovery of evoked potentials from slices of rat olfactory cortex after anoxia. Br J Pharmacol 1994;111:1221-1227.
35. Bates D, Ashford E, Dawson R, et al. Subcutaneous sumatriptan during the migraine aura. Neurology 1994;44: 1587-1592.
36. Olesen J, Diener HC, Schoenen J, Hettiarachchi J. No effect of eletriptan administration during the aura phase of migraine. Eur J Neurol 2004;11:671-677.
37. Anttila V, Stefansson H, Kallela M, et al. Genome-wide association study of migraine implicates a common susceptibility variant on 8q22.1. Nat Genet 2010;42:869-873.
38. Andreou AP, Goadsby PJ. Therapeutic potential of novel glutamate receptor antagonists in migraine. Expert Rev Investig Drugs 2009;18:789-804.